Trial Profile
A phase 1/2 study to evaluate the safety and efficacy of the combination of Imfinzi (durvalumab) and sacituzumab govitecan as a frontline treatment of patients with triple-negative breast cancer (TNBC) and urothelial cancer (UC)
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Sacituzumab govitecan (Primary)
- Indications Breast cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2018 New trial record
- 23 Jul 2018 According to an Immunomedics media release, Part one of the two-part Phase 1/2 studies will be co-funded by the two companies. Immunomedics will supply the study drug and AstraZeneca will utilize its existing clinical trial infrastructure to accelerate the enrollment of the sacituzumab govitecan and durvalumab combination.